| Name: | Time: | Location: | Type: | Title: |
|---|---|---|---|---|
| Galen Goldscheitter | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #1054, Presenter | MASLD and PNPLA3I148M Associate with Skeletal Fragility Via Deleterious Liver-Bone Crosstalk |
| Richard Sterling | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #1407, Presenter | A Novel Score for Predicting Return for Drinking after Alcoholic Hepatitis |
| Anas Aljabi | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #1441, Presenter | FIB-4 Predicts Long-Term Outcomes after SVR in HCV Patients with Cirrhosis: Gone but Not to Be Forgotten |
| Puneet Puri | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #1492, Presenter | When PEth Gets an AUDIT-C — Implications on Classification, Misclassification and Outcomes in Steatotic Liver Disease |
| Grayson Way | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #1494, Presenter | Metabolic Signatures of Bile Acid and Sphingolipid Dysregulation in Alcohol-Associated Hepatitis and Cirrhosis |
| Jasmohan Bajaj | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #1580, Presenter | Fecal Microbiota Transplant from Specific Human Donors Reduce Alcohol Preference and Intake in Conventional Female Mice |
| Ekaterina Smirnova | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #1586, Presenter | The Use of Wearable Alcohol Measurement Devices Increases Precision of Alcohol Intake Assessment in Patients with Alcohol-Associated Hepatitis |
| Presenters | ||||
| Arun Sanyal | 11:10-11:30 a.m. | Hall A (General Session), Concourse Level | Presenter | Metabolic Dysfunction-Associated Steatotic Liver Disease Effects on the Brain, Heart, Pancreas, and Other Organs |
| Juan Pablo Arab | 2:30-2:45 p.m. | Room 209, Level 2 | Presenter | Early Transplantation for Alcohol-Associated Liver Disease: Bridging Gaps in Access and Equity |
| Hanna Blaney | 2:40-3 p.m. | Room 207, Level 2 | Moderator | The New Definition of Obesity and Pharmacologic Interventions |
| Jasmohan Bajaj | 3:48-3:55 p.m. | Site A, Level 3 | Presenter | Secondary SBP Prophylaxis Worsens Survival Without Affecting Liver Transplant Rates in Veterans with Cirrhosis Followed After their First Decompensation |
| Juan Pablo Arab | 4-5:30 p.m. | Room 207, Level 2 | Moderator | Obesity and Addiction Medicine in Liver Disease: Translating Science into Practice, Part 2—Interventions and Long-Term Management |
| Jasmohan Bajaj | 4:10-4:30 p.m. | Hall A (General Session), Concourse Level | Presenter | Liver Disease as a Contributor to Dementia |
School of Medicine
The Liver Meeting 2025
A delegation from the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, led by Institute Director Arun Sanyal, M.D., FAASLD, and Chief Scientific Officer Saul Karpen, M.D., Ph.D., FAASLD, will attend The Liver Meeting 2025, in Washington, D.C., Nov. 7-11.
VCU @ TLM day by day
To see the full list of VCU's presence at The Liver Meeting 2025, select a date below:
Friday, Nov. 7
Saturday, Nov. 8
| Name: | Time: | Location: | Type: | Title: |
|---|---|---|---|---|
| Arun Sanyal | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #2075, Presenter | SomaSignal Defined MASH Disease Components Are Prognostic of Secondary Cardiovascular Disease – A Post-Hoc Analysis of the Select Trial |
| Vinay Jahagirdar | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #2114, Presenter | Changes in the Fibrosis-4 (FIB-4) Score Accurately Reflects the Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease |
| Jasmohan Bajaj | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #2324, Presenter | A Machine Learning Model to Reduce Unnecessary Paracentesis for SBP Exclusion Has Excellent Performance in a Recent Nationwide Cirrhosis Cohort |
| Jasmohan Bajaj | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #2426, Presenter | Olfactory and Gustatory Impairment in Cirrhosis Correlates with Renal Insufficiency and Cognitive Impairment and Negatively Impacts Perceived Ability to Eat |
| Jasmohan Bajaj | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #2347, Presenter | Rifaximin Monotherapy Is Superior to Lactulose Monotherapy in Reducing the Risk of Hepatic Encephalopathy Recurrence: Insights from a Subgroup Analysis by Baseline Characteristics |
| Jasmohan Bajaj | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #2355, Presenter | Pre-Admission Rifaximin Use Is Not Associated with Infection with Drug Resistant Organisms in a Global Cohort of Inpatients with Cirrhosis |
| Lourianne Cavalcante | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #2378, Presenter | Liver Stiffness as a Predictor of Myopenia and Functional Muscle Decline in Advanced Liver Disease: A Call for Refined Diagnostic Cutoffs |
| Vinay Jahagirdar | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #2381, Presenter | It Is Cost-Effective to Screen and Treat Patients with Dementia for Undiagnosed Hepatic Encephalopathy |
| Lourianne Cavalcante | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #2424, Presenter | Vibration-Controlled Transient Elastography as a Non-Invasive Predictor of Sarcopenia in Cirrhosis: Establishing a Threshold for Risk Stratification |
| Vinay Jahagirdar | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #2425, Presenter | Using FIB-4 to Uncover Undiagnosed Cirrhosis in Patients with Dementia: A Quality Improvement Initiative |
| Presenters | ||||
| Richard Sterling | 8:15-8:30 a.m. | Room 146B, Level 1 | Presenter | Noninvasive Tests to Assess Hepatic Fibrosis in Chronic Hepatitis B: Elastography, FIB-4, APRI, and ELF Score |
| Juan Pablo Arab | 9-9:15 a.m. | Ballroom A, Level 3 | Presenter | Natural History and Disease Progression of MetALD |
| Vinay Jahagirdar | 11 a.m.-12:30 p.m. | Room 146C, Level 1 | Panelist | Best of the Liver Fellow Network |
| John Grady | 11 a.m.-12:30 p.m. | Room 146C, Level 1 | Panelist | Best of the Liver Fellow Network |
| Jasmohan Bajaj | 11:30-11:45 a.m. | Room 146A, Level 1 | Presenter | Debate: Is It Time to Rethink Spontaneous Bacterial Peritonitis Prophylaxis? (PRO) |
| Juan Pablo Arab | 2-3:30 p.m. | Convention Center: Ballroom A‚ Level 3 | Moderator | Steatotic Liver Disease: What You Need to Know, Part 2. Dual Threats—Advancing Research and Care in Steatotic Liver Disease |
| Chris Green | 2:15-2:30 p.m. | Room 146B, Level 1 | Presenter | Sphingosine kinase 2 in sexual dimorphism of hepatocellular carcinoma |
| Jasmohan Bajaj | 3:15-3:30 p.m. | Ballroom B, Level 3 | Presenter | Emerging Therapeutics for Acute-on-Chronic Liver Failure |
| Vinay Jahagirdar | 3:45-4:45 p.m. | Room 201, Level 2 | Panelist | The Liver Fellow Network Presents: Ask Me Anything about Transplant Hepatology Training and Early Career |
Sunday, Nov. 9
| Name: | Time: | Location: | Type: | Title: |
|---|---|---|---|---|
| Puneet Puri | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #3052, Presenter | Metabolic Dysfunction Associated Steatotic Liver Disease: A Precision Digital Therapeutics Pilot Feasibility Randomized |
| Jawaid Shaw | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #3068, Presenter | Appropriate Interventions Help to Reduce 30-Day Hospital Readmissions for Cirrhosis: A Scoping Review |
| Sai Patel | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #3077, Presenter | Optimizing Transitions of Care for Liver Cirrhosis Patients: A Retrospective Analysis of Inpatient Encounter Data on 30-Day Readmissions |
| Prabhat Kumar | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #3142, Presenter | Hormone-Replacement Therapy Reduces Risk of Hepatocellular Carcinoma and Slows Chronic Liver Disease Progression in Post-Menopausal Women: A Propensity-Match TriNetX Analysis |
| Michael Eiswerth | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #3395, Presenter | Does IQR/median of liver stiffness measurement impact the accuracy of predicting of advanced fibrosis in MASLD? |
| Richard Sterling | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #3522, Presenter | The Natural History of Spur Cell Anemia after Liver Transplantation and its Impact on Survival |
| Alexis Kim | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #3597, Presenter | Defining Weight Trajectory after Liver Transplantation Using Generative Artificial Intelligence |
| Nicole Lulkin | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #3611, Presenter | Application of New Steatotic Liver Disease Nomenclature to Liver Transplant Recipients |
| Presenters | ||||
| Juan Pablo Arab | 8:30-8:50 a.m. | Ballroom A, Level 3 | Presenter | Endpoints in patients with compensated cirrhosis or compensated advanced chronic liver disease (cACLD) |
| Jasmohan Bajaj | 11 a.m.-12:30 p.m. | Room 146B, Level 1 | Panelist | American Association for the Study of Liver Diseases and Asian Pacific Association for the Study of the Liver Joint Symposium (AASLD/APASL): Acute-on-Chronic Liver Failure—Contrasting Perspectives from the East and West |
| Juan Pablo Arab | 2-3:30 p.m. | Room 146A, Level 1 | Moderator | Academic Advancement, Promotion, and Tenure for Under-Represented Groups in Hepatology |
| Arun Sanyal | 2:30-2:45 p.m. | Hall A (General Session), Concourse Level | Abstract Parallel #0149, Presenter | Safety and Efficacy of Cotadutide, A Dual GLP-1 and Glucagon Receptor Agonist in Adults with Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis: Final Results: From A Phase 2b Randomized, Placebo-Controlled, Proof-of Concept Study |
| Arun Sanyal | 5:15-5:30 p.m. | Ballroom A, Level 3 | Abstract Parallel #0166, Presenter | GLP-1 Receptor Agonists Are Superior to Bariatric Surgery for Prevention of All Cause Mortality and Major Adverse Liver Outcomes in Type 2 Diabetes Mellitus and Obesity in Real World Clinical Practice |
Monday, Nov. 10
| Name: | Time: | Location: | Type: | Title: |
|---|---|---|---|---|
| Sahaj Rathi | 8-8:15 a.m. | Room 202, Level 2 | Abstract #0063, Abstract Parallel Presenter | Outcomes of Endoscopic Ultrasound-Guided Shunt Modulation for Recurrent Hepatic Encephalopathy: Pushing Boundaries of Endohepatology |
| Vinay Jahagirdar | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #4052, Presenter | Resmetirom Improves Mortality, Liver and Cardio-Renal-Metabolic (CRM) Outcomes in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease in Routine Clinical Practice |
| Vinay Jahagirdar | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #4069, Presenter | Prescribing Patterns and Clinical Characteristics of Resmetirom Recipients: Real-World Insights |
| Jasmohan Bajaj | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #4125, Presenter | Secondary SBP Prophylaxis Worsens Survival Without Affecting Liver Transplant Rates in Veterans with Cirrhosis Followed After their First Decompensation |
| Kavin Parmar | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #4136, Presenter | Establishing A Rank-Ordered Hierarchy of ACLF Related Mortality Risk Associated with Organ Support in Real World Clinical Practice |
| Vasily Yakovlev | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #4261, Presenter | Exosome-dependent mechanism of Liver Regeneration After Partial Hepatectomy |
| Jasmohan Bajaj | 8 a.m.-5 p.m. | Exhibit Hall D & E | Poster #4318, Presenter | A gut metagenomic profile distinguishes compensated cirrhosis from healthy controls across multiple country cohorts |
| Jasmohan Bajaj | 8:30-8:45 a.m. | Room 146A, Level 1 | Abstract #0237, Abstract Parallel Presenter | Salivary microbiome and serum metabolomics add to clinical biomarkers to predict 6-month hospitalizations in a multi-center cirrhosis outpatient cohort |
| S. "Obi" Aseem | 8-8:15 a.m. | Exhibit Hall D & E | Abstract #4191 Presenter | Cholangiocyte RUNX1 Orchestrates Fibrogenic and Inflammatory Signaling to Drive Biliary Fibrosis |
| Presenters | ||||
| Arun Sanyal | 9:45-10:45 a.m. | Ballroom A, Level 3 | Panelist | Breaking News in MASH: FDA's Pathway for NIT-Driven Endpoints |
| Jasmohan Bajaj | 11:10-11:20 a.m. | Room 207, Level 2 | Presenter | Finding Your Research Niche, Purpose, and Community |
| Arun Sanyal | 12:30-2 p.m. | Room 150, Level 1 | Panelist | Getting to Grip with Non-Invasive Tests to Assess Liver Fibrosis & Patient Eligibility for Novel MASH Therapies |
| Jasmohan Bajaj | 2:30-2:45 p.m. | Room 202, Level 2 | Abstract #0143, Abstract Parallel | Frailty, Cognitive Impairment and Comorbid Conditions add to Cirrhosis Severity in Prediction of 12-month Hospitalizations in a Multi-center Outpatient Cirrhosis Cohort |
| Richard Sterling | 3:45-4:45 p.m. | Room 146C, Level 1 | Moderator | Early Career Investigator Essentials: Adapting and Excelling in Challenging Times |
| Hannah Lee | 6:15-6:30 p.m. | Room 146A, Level 1 | Abstract #0140, Abstract Parallel | Health literacy is an important determinant of health outcomes: Identifying risk factors for poor health literacy in chronic liver disease |
Abstracts by VCU authors and co-authors
The following abstracts from VCU authors and co-authors are included in this year’s abstract supplement:
0005 | Long-Term Data of Elafibranor in Primary Sclerosing Cholangitis: Interim Safety and Efficacy Data from the Ongoing Openlabel Extension of the Elmwood Phase II Trial
Velimir Luketic
0007 | Efruxifermin Was Associated with Improvements in Multiple Non-Invasive Tests Indicative of Fibrosis Regression in Participants with Compensated Cirrhosis Due to MASH (Symmetry)
Arun Sanyal
0010 | Weight-Dependent and Independent Effects of Semaglutide in Participants with MASH: Secondary Analysis of the Phase 3 Essence Trial
Arun Sanyal
0023 | Hepatic Dysfunction and Hepatic Failure Cutoffs in Cirrhosis Patients with ACLF
Jasmohan Bajaj
0041 | Incretin-based Therapies and Post-Bariatric Alcohol Use Disorder: A Propensity-Matched Cohort Study
Boutros Fakhoury
0044 | Validation of Noninvasive Clinical Pathways to Identify Advanced Fibrosis in MetALD and ALD
Arun Sanyal, Richard Sterling, Juan Pablo Arab
0086 | A RWE-Based Characterization of Patients Admitted in U.S. Hospital for an Event of Acute Decompensation Highlights Differences in the Management of Inpatients
Arun Sanyal
0090 | A Multi-omic Blood-based Model Accurately Predicts Liver Related Events in Patients with Cirrhosis after Hepatitis C Virus Cur with Direct Acting Antivirals
Jasmohan Bajaj
0102 | Getting to Implementation: A Stepped Wedge Cluster Randomized Trial of a Hospital-level Intervention to Improve Hepatocellular Carcinoma Surveillance
Jasmohan Bajaj
0110 | The Impact of Cannabinoids on the Risk of Alcohol-Associated Liver Disease
Boutros Fakhoury
0147 | Improvements in Non-Invasive Biomarkers and Biopsy Responses with the Glucagon Receptor/Glucagon-Like Peptide-1 Receptor Dual Agonist Survodutide: Concordance Analysis from a Phase 2 Trial in People with Metabolic Dysfunction–Associated Steatohepatitis and Fibrosis
Arun Sanyal
0148 | A Randomized, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of Combination Treatment with Semaglutide, Cilofexor and Firsocostat in Patients with Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (Wayfind)
Arun Sanyal
0149 | Safety and Efficacy of Cotadutide, A Dual GLP-1 and Glucagon Receptor Agonist in Adults with Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis: Final Results: From A Phase 2b Randomized, Placebo-Controlled, Proof-of Concept Study
Arun Sanyal
0160 | One-Year Changes in ALT and LSM, But Not in CAP, Predict Long-Term Liver Outcomes in Patients with MASLD
Arun Sanyal
0166 | GLP-1 Receptor Agonists Are Superior to Bariatric Surgery for Prevention of All Cause Mortality and Major Adverse Liver Outcomes in Type 2 Diabetes Mellitus and Obesity in Real World Clinical Practice
Ana Oliveira, Kavin Parmar, Vinay Jahagirdar, Arun Sanyal
0171 | The Impact of Metabolic Risks and Alcohol Use on Disease Severity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Juan Pablo Arab
0178 | HSD17B13 RS72613567 Variant Is Associated with Histological Progression and Regression in MASLD and It Also Significantly Modifies the Effect of BMI Change on Liver Histology
Arun Sanyal
0204 | Fractures in Patients with Alagille Syndrome: Data from the Gala Study Group
Saul Karpen
0237 | Salivary Microbiome and Serum Metabolomics Add to Clinical Biomarkers to Predict 6-Month Hospitalizations in a Multi-Center Cirrhosis Outpatient Cohort
Jasmohan Bajaj, Jawaid Shaw, Leroy Thacker
1054 | MASLD and PNPLA3I148M Associate with Skeletal Fragility Via Deleterious Liver-Bone Crosstalk
Galen Goldscheitter, Mulugeta Seneshaw, Faridoddin Mirshahi, Ronnie Li, Henry Donahue, Arun Sanyal
1070 | Western Diet Exacerbates c–Myc–Induced Hepatocarcinogenesis in Diamond Mice
Yun-Ling Tai, Nan Wu, Derrick Zhao, Grayson Way, Meiyi Song, Hui Li, Sareh Bayatpour, Lianyong Su, Xuan Wang, Emily Gurley, Phillip Hylemon, Arun Sanyal, Huiping Zhou
1407 | A Novel Score for Predicting Return to Drinking After Alcoholic Hepatitis
Arun Sanyal, Richard Sterling
1441 | FIB-4 Predicts Long-Term Outcomes after SVR in HCV Patients with Cirrhosis: Gone but Not to Be Forgotten
Anas Aljabi, Husam Mikati, Reena Cherian, Shawn Lewis, Leah Blatzer, Richard Sterling
1444 | Hepatocyte Aging Signature from RNA-seq Is Significantly Associated with Histologic Severity in Human MASLD, Independent of Chronologic Age
Arun Sanyal
1492 | When PEth Gets an AUDIT-C — Implications on Classification, Misclassification and Outcomes in Steatotic Liver Disease
Puneet Puri
1494 | Metabolic Signatures of Bile Acid and Sphingolipid Dysregulation in Alcohol-Associated Hepatitis and Cirrhosis
Grayson Way, Lianyong Su, Derrick Zhao, Yun-Ling Tai, Nan Wu, Arun Sanyal, Phillip Hylemon, Hongkun Lu, Huiping Zhou
1508 | Non-Absorbable Antibiotics Worsen Alcohol-Associated Liver Disease in Gastric Acid-Suppressed Mice
Jasmohan Bajaj
1564 | Disruption of HuR Aggravates Alcohol-Induced Liver Inflammation through Altered Bile Acid Signaling and H19 Upregulation
Nan Wu, Yun-Ling Tai, Derrick Zhao, Hui Li, Grayson Way, Meiyi Song, Sareh Bayatpour, Lianyong Su, Xuan Wang, Emily Gurley, Phillip Hylemon, Arun Sanyal, Huiping Zhou
1575 | Accelerated Progression to Cirrhosis and Hepatic Decompensation in MetALD and ALD Compared to MASLD: A Global Study
Richard Sterling, Arun Sanyal, Juan Pablo Arab
1580 | Fecal Microbiota Transplant from Specific Human Donors Reduce Alcohol Preference and Intake in Conventional Female Mice
Jasmohan Bajaj
1586 | The Use of Wearable Alcohol Measurement Devices Increases Precision of Alcohol Intake Assessment in Patients with Alcohol-Associated Hepatitis
Ekaterina Smirnova, Albert Arias, Juan Pablo Arab Verdugo, Amon Asgharpour, Sara O'Connor, Frederick Moeller, Arun Sanyal
2019 | Comparison of Digital Images Versus Glass Slides for the Histopathological Evaluation of Liver Biopsy Samples According to the NASH-CRN Scoring System for MASH: A Validation Performed as Part of the NATiV3 Study
Arun Sanyal
2020 | Zone-Specific Fibrosis Reductions Induced by Pegozafermin over 24 Weeks Are Similar in Non-Cirrhotic (F2/F3) and Cirrhotic (F4) MASH
Arun Sanyal
2022 | Single Circulating Biomarkers sVCAN-, and TSP2 Achieved Effective Prognostic Performances for the Detection of Fibrosis Progression to Cirrhosis
Arun Sanyal
2030 | Circular RNA Profiling Reveals IGF2BP-linked Regulatory Networks in Human Metabolic Dysfunction-Associated Steatohepatitis
Sareh Bayatpour, Hui Li, Grayson Way, Nan Wu, Yunling Tai, Derrick Zhao, Meiyi Song, Lianyong Su, Emily Gurley, Xuan Wang, Phillip Hylemon, Arun Sanyal, Huiping Zhou
2034 | Hepatocellular Carcinoma Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease
Arun Sanyal
2041 | Performance of FIB-4 Varies Greatly According to Age Groups in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Data from Global MASLD Project
Juan Pablo Arab
2050 | Combining sVCAM-1 Or TSP2 with FIB-4 for an Improved Detection of Patients with Cirrhosis
Arun Sanyal
2075 | SomaSignal Defined MASH Disease Components Are Prognostic of Secondary Cardiovascular Disease – A Post-Hoc Analysis of the Select Trial
Arun Sanyal
2086 | Second Harmonic Generated Imaging with qFibrosis Provides Quantitative Information on Fibrosis Severity and Predicts the Future Course of Fibrosis in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
Ekaterina Smirnova, Shailaja Reddy, Faridoddin Mirshahi, Arun Sanyal
2114 | Changes in the Fibrosis-4 (FIB-4) Score Accurately Reflects the Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease
Vinay Jahagirdar, Philip Newsome, Arun Sanyal
2119 | Meta-Analysis of the Performance of the Enhanced Liver Fibrosis (ELF) Test to Identify Significant Fibrosis, Advanced Fibrosis and Cirrhosis in Patients with MASLD
Arun Sanyal
2324 | A Machine Learning Model to Reduce Unnecessary Paracentesis for SBP Exclusion Has Excellent Performance in a Recent Nationwide Cirrhosis Cohort
Jasmohan Bajaj
2325 | Impact of Bacterial Infection on Clinical Outcomes in Patients with Acute Decompensation: Real-World Evidence Insights
Jasmohan Bajaj, Arun Sanyal
2326 | Olfactory and Gustatory Impairment in Cirrhosis Correlates with Renal Insufficiency and Cognitive Impairment and Negatively Impacts Perceived Ability to Eat
Jasmohan Bajaj, Michael Fuchs, Brian Davis, Puneet Puri
2347 | Rifaximin Monotherapy is Superior to Lactulose Monotherapy in Reducing the Risk of Hepatic Encephalopathy Recurrence
Jasmohan Bajaj
2355 | Pre-admission Rifaximin Use Is Not Associated with Infection with Drug Resistant Organisms in a Global Cohort of Inpatients with Cirrhosis
Jasmohan Bajaj, Jawaid Shaw, Somaya Albhaisi, Leroy Thacker, Brian Bush
2378 | Liver Stiffness as a Predictor of Myopenia and Functional Muscle Decline in Advanced Liver Disease: A Call for Refined Diagnostic Cutoffs
Lourianne Nascimento Cavalcante
2382 | It Is Cost-Effective to Screen and Treat Patients with Dementia for Undiagnosed Hepatic Encephalopathy
Vinay Jahagirdar, Leroy Thacker, Michael Weissberger, Jasmohan Bajaj
2397 | Enhanced Rifaximin Drug Release Across Gastrointestinal Tract pH Conditions with Soluble Solid Dispersion (SSD) Immediate-Release (IR) Tablets: A Comparative In Vitro Study Versus Rifaximin 550 Mg Tablet Formulation
Jasmohan Bajaj, Arun Sanyal
2424 | Vibration-Controlled Transient Elastography as a Non-Invasive Predictor of Sarcopenia in Cirrhosis: Establishing a Threshold for Risk Stratification
Lourianne Nascimento Cavalcante
2425 | Using FIB-4 to Uncover Undiagnosed Cirrhosis in Patients with Dementia: A Quality Improvement Initiative
Vinay Jahagirdar, Michael Weissberger, Jawaid Shaw, Dan Park, Peter Boling, Jasmohan Bajaj
2439 | Finerenone in the Management of Portal Hypertension
Boutros Fakhoury
2470 | Patients with Decompensated Cirrhosis Have Reduced Fat and Muscle Volumes Compared to Compensated Cirrhosis: A Whole-Body MRI Study
Danielle Kirkman, Amon Asgharpour, Vaishali Patel, Geneva Roache, Arun Sanyal
2487 | Effect of Hypertension on Long-Term Adverse Clinical Outcomes and Liver Fibrosis Progression in Metabolic Dysfunction-Associated Steatotic Liver Disease
Arun Sanyal, Amon Asgharpour
2556 | Any Amount of Alcohol Intake Increases the Risk of Significant Fibrosis and Fibrotic MASH in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - Insights from 7189 Patients from Indian Consortium on MASLD (ICOM-D)
Arun Sanyal
2562 | Genetic Risk of Steatotic Liver Disease and its Severity among People Living with HIV
Richard Sterling
2565 | Global Prevalence and Risk of High-Risk Genetic Polymorphisms in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis
Kaanthi Rama, Vinay Jahagirdar, Ronnie Li, Anas Aljabi, Ambuja Banerjee, John Cyrus, Stephen Hoang, Juan Pablo Arab
2618 | Clinical Characteristics and Outcomes of Patients with Presumed MASLD Who Meet MetALD Criteria in the Target-Nash Cohort
Arun Sanyal
3052 | Metabolic Dysfunction Associated Steatotic Liver Disease: A Precision Digital Therapeutics Pilot Feasibility Randomized
Puneet Puri
3068 | Appropriate Interventions Help to Reduce 30-Day Hospital Readmissions for Cirrhosis: A Scoping Review
Jawaid Shaw, John Cyrus, Richard Sterling
3077 | Optimizing Transitions of Care for Liver Cirrhosis Patients: A Retrospective Analysis of Inpatient Encounter Data on 30-Day Readmissions
Sai Patel, Ayush Kaushish, Michael Moseley, Alexis Kim, Allison Ladetto, Hannah Lee, Carolyn Marcelo
3087 | FIB-4 Risk Stratification Model Can Predict Liver-Related Outcomes of MASLD Patients Receiving Care in Non-Specialty/Primary Care Settings
Arun Sanyal
3142 | Hormone-Replacement Therapy Reduces Risk of Hepatocellular Carcinoma and Slows Chronic Liver Disease Progression in Post-Menopausal Women: A Propensity-Match TriNetX Analysis
Prabhat Kumar, Archana Kharel, Michael Eiswerth, Vinay Jahagirdar, Hasan Alroobi, Gowthami Kanagalingam, Scott Matherly
3179 | Hepatocellular Adenoma (HCA): Growth and Outcomes in Pregnancy
Gowthami Kanagalingam
3342 | Continuous Digital Pathology Scoring Reveals Fibrosis Reversal and Treatment Benefit of Lanifibranor: Insights from A Preclinical Rodent Model
Arun Sanyal
3347 | Combining Digital Pathology and Biomarkers Offer a Translational Framework to Quantify Fibrosis and Lanifibranor Treatment Response in a TAA-Induced Cirrhosis Model
Arun Sanyal
3348 | High-Resolution Digital Pathology Demonstrates Antifibrotic and Anti-Inflammatory Effects of Lanifibranor in Therapeutic Interventions Using TAA-Induced Cirrhotic Rodent Models
Arun Sanyal
3395 | Does IQR/Median of Liver Stiffness Measurement Impact the Accuracy of Predicting of Advanced Fibrosis in MASLD?
Michael Eiswerth, Arun Sanyal, Richard Sterling
3434 | Risk Stratification for Waitlist Dropout in HCC Patients beyond UCSF Criteria: A Competing-Risks Analysis
Boutros Fakhoury
3522 | The Natural History of Spur Cell Anemia after Liver Transplantation and its Impact on Survival
Hasan Alroobi, Kevin Houston, Richard Stravitz, Amon Asgharpour, Scott Matherly, Joel Wedd, Hannah Lee, Vaishali Patel, Sayed Aseem, David Bruno, Richard Sterling
3597 | Defining Weight Trajectory after Liver Transplantation Using Generative Artificial Intelligence
Alexis Kim, Linxi Lee, Reem Hamraz, Madison Nguyen, Rehan Razzaq, Vaishali Patel, Amon Asgharpour, Idris Yakubu, Lesslee Garland, Kavin Parmar, Samarth Patel, Anh Bui
3611 | Application of New Steatotic Liver Disease Nomenclature to Liver Transplant Recipients
Nicole Lulkin, Madison Nguyen, Alexis Kim, Vaishali Patel, Amon Asgharpour, Idris Yakubu, Anh Bui
4015 | Vitamin E Dosing Study (VEDS) in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized-Placebo Controlled Trial
Arun Sanyal
4033 | MRI-PDFF ≥ 70% Reduction Was Associated with Fibrosis Improvement with Tirzepatide: Post-Hoc Analysis of the Synergy-NASH Phase 2b Trial
Arun Sanyal
4039 | Survodutide Improved Liver Histology in People with MASH and Moderate-To-Severe Fibrosis Regardless of Age, Sex, Ethnicity, or Type 2 Diabetes: Subgroup Analysis of a Randomized Phase 2 Trial
Arun Sanyal
4042 | Efficacy Response in Subgroups of Participants in Essence Demonstrate that Semaglutide Is Effective in Improving Liver Fibrosis across A Diverse Population
Arun Sanyal
4052 | Resmetirom Improves Mortality, Liver and Cardio-Renal-Metabolic (CRM) Outcomes in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease in Routine Clinical Practice
Vinay Jahagirdar, Kavin Parmar, Neha Shah, Amon Asgharpour, Velimir Luketic, Ekaterina Smirnova, Juan Pablo Arab, Arun Sanyal
4069 | Prescribing Patterns and Clinical Characteristics of Resmetirom Recipients: Real-World Insights
Vinay Jahagirdar, Kaanthi Rama, Amon Asgharpour, Richard Sterling, Arun Sanyal, Juan Pablo Arab
4127 | Systemic Challenges in Managing Acute-On-Chronic Liver Failure (ACLF) in the U.S.: Diagnostic Delays, Referral Barriers, and Fragmented Post-Discharge Care
Jasmohan Bajaj, Arun Sanyal
4136 | Establishing A Rank-Ordered Hierarchy of ACLF Related Mortality Risk Associated with Organ Support in Real World Clinical Practice
Kavin Parmar, Ana Oliveira, Vinay Jahagirdar, Ekaterina Smirnova, Juan Pablo Arab, Jasmohan Bajaj, Arun Sanyal
4184 | Liver-Specific S1PR2 Deletion Reduces Hepatic Injury and Fibrosis in a Mouse Model of Primary Sclerosing Cholangitis
Meiyi Song, Derrick Zhao, Hui Li, Sayed Obaidullah Aseem, Grayson Way, Nan Wu, Yunling Tai, Sareh Bayatpour, Lianyong Su, Xuan Wang, Emily Gurley, Phillip Hylemon, Arun Sanyal, Huiping Zhou
4190 | The H19–cirCAFF3–HuR Axis: A Novel Regulatory Circuit in Cholestatic Liver Fibrosis
Hui Li, Grayson Way, Yun-Ling Tai, Nan Wu, Meiyi Song, Sareh Bayatpour, Derrick Zhao, Sayed Obaidullah Aseem, Lianyong Su, Xuan Wang, Emily Gurley, Phillip Hylemon, Saul Karpen, Arun Sanyal, Huiping Zhou
4191 | Cholangiocyte RUNX1 Orchestrates Fibrogenic and Inflammatory Signaling to Drive Biliary Fibrosis
Sayed Obaidullah Aseem, Jing Wang, Grayson Way, Yunling Tai, Derrick Zhao, Xuan Wang, Emily Gurley, Phillip Hylemon, Saul Karpen, Arun Sanyal, Huiping Zhou
4261 | Exosome-dependent mechanism of Liver Regeneration After Partial Hepatectomy
Vasily Yakovlev, Mina McGinn, Christopher Rabender, Ross Mikkelsen
4295 | Molecular Relationship Between Steatohepatitis and Advanced Fibrosis in Human MASLD: An Investigation Based on Multiple Human RNA-seq Datasets
Arun Sanyal
4318 | A Gut Metagenomic Profile Distinguishes Compensated Cirrhosis from Healthy Controls across Multiple Country Cohorts
Jasmohan Bajaj
4504 | Bold and Bold-Ext, the First Global Phase III Clinical Program to Evaluate the Long-Term Efficacy and Safety of Odevixibat in Infants with Biliary Atresia after Kasai Hepatoportoenterostomy—Study Design and Current Status
Saul Karpen
4598 | Exhibit Age-Dependent Liver Injury and Unfolded Protein Response (UPR) Activation
Saul Karpen
4649 | Portal Vein Thrombosis (PVT) Increases Short-term Mortality among Hospitalized Decompensated Patients in a Global Cohort
Jasmohan Bajaj, Jawaid Shaw, Somaya Albhaisi, Leory Thacker, Brian Bush